These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17267340)

  • 1. The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
    Dobay O; Rozgonyi F; Ghidán A; Matuz M; Nagy K; Amyes SG
    J Chemother; 2006 Dec; 18(6):624-7. PubMed ID: 17267340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
    Patel SN; McGeer A; Melano R; Tyrrell GJ; Green K; Pillai DR; Low DE;
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3703-8. PubMed ID: 21628545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
    Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
    Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
    Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
    Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
    Adam HJ; Schurek KN; Nichol KA; Hoban CJ; Baudry TJ; Laing NM; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2007 Jan; 51(1):198-207. PubMed ID: 17088485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
    De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
    J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG; Rodríguez-Tarazona RE; García-Rodríguez JA; Muñoz-Bellido JL
    Int J Antimicrob Agents; 2009 Sep; 34(3):252-4. PubMed ID: 19243922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
    Patel SN; Melano R; McGeer A; Green K; Low DE
    Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
    Etienne M; Croisier D; Charles PE; Lequeu C; Piroth L; Portier H; Drlica K; Chavanet P
    J Infect Dis; 2004 Oct; 190(8):1472-5. PubMed ID: 15378440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.